Aspects microbiologiques des infections pulmonaires au cours de la mucoviscidose

Medecine Therapeutique Pediatrie

Volumn 1, Issue 3, 1998, Pages 235-240

  Chabanon, Gérard ^a   Segonds, Christine ^a   Marty, Nicole ^a   Dournes, Jean Luc ^a   Agueda, Louis ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2042538861     PISSN: 12865494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Gilligan P.H. 1991. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 4 : 35-51.
2. Anderson D.H. 1949. Therapy and prognosis of fibrocystic disease of the pancreas, Pediatrics 3 : 406-417.
3. Høiby N. 1982. Microbiology of lung infection in CF patients. Acta Paediatr Scand 301 (suppl.) : 33-54.
4. Montalembert de M., Boukadida J., Berche P. 1991. Aspects bactériologiques de la mucoviscidosc. Rev Fr Lab 220 : 57-64.
5. Chabanon G., et al. 1997. Epidemiology of the primary acquisition of Pseudomonas aeruginosa by cystic fibrosis patients : a retrospective study. 15th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID). Paris, 22-23 mai.
6. Aly R., Levit S. 1987. Adherence of Staphylococcus aureus to squamous epithelium : role of fibronectin and teichoic acid. Rev Infect Dis 9 (suppl. 4) : 341-350.
7. Doring G., Knight R., Bellon G. 1995. Immunology of cystic fibrosis. In : Hoddson M.E., Geddes D.M., eds. Texbook of cystic fibrosis. Londres : Chapman and Hall, 99-130.
8. Boxerbaum B., Jacobs M.R., Cechner R.L. 1988. Prevalence and significance of methicillin resistant Staphylococcus aureus in patients with cystic fibrosis. Pediatr Pulmon 4 : 159-163.
9. Zuelzer W.W., Newton W.A. Jr. 1950. The pathogenesis of fibrocystic disease of the pancreas: a study of 36 cases with special reference to pulmonary lesions. Pediatrics 4 : 53-69.
10. Woods D.E., Strauss D.C., Johanson W.C., Bass J.A. 1981. Role of fibronectin in the prevention of adherence of Pseudomonas aeruginosa to mammalian buccal epithelial cells. J Infect Dis 143 : 786-790.
11. Bauernfeind A., Emminger G., Horl G., Lorbeer H., Przylenk B., Weisslein-Pfister C. 1987. Selective pressure of antistaphylococcal chemotherapeutics in favor of Pseudomonas aeruginosa in cystic fibrosis. Infection 15 : 469-470.
12. Doggett R.C., Harrison C.M., Stillwell R.N., Wallis E.S. 1966. An atypical Pseudomonas aeruginosa associated with cystic fibrosis of the pancreas. J Pediatr 68 : 215-221.
13. Rasquier C., Dournes J.L, Chabanon G., Maity N. 1996. The biosynthesis of Pseudomonas aeruginosa alginate regulation of a virulence factor. Bull Inst Pasteur 94 : 139-149.
14. Berry A., Devault J.D., Chakrabarty A.M. 1989. High osmolarity is a signal for enhanced algD transcription in mucoid and non mucoid Pseudomonas aeruginosa strains. J Bact 171 : 2312-2317.
15. Marty N., Chabanon G., Montrozier H. 1992. Influence of nutrient media on the chemical composition of the exopolysaccharide from mucoid and non mucoid Pseudomonas aeruginosa. FEMS Microbiol Left 98 : 35-44.
16. Aubry J.C, Marty N., Doumes J.L., Didier A., Chabanon G., Léophonte P. 1995. Followup of Pseudomonas aeruginosa infection in idiopathic bronchectasies : phenotypic and genotypic characteristics. Am J Respir Critical Care Med 151 : A467.
17. Costerton J.W., Lam J., Chan R. 1983. The role of the microcolony mode of growth in the pathogenesis of Pseudomonas aeruginosa infections. Rev Infect Dis 5 : S867-S873.
18. Baltimore R.S., Mitchell M. 1980. Immunologic investigations of mucoid strains of Pseudomonas aeruginosa : comparison of susceptibility to opsonic antibody in mucoid and non mucoid strains. J Infect Dis 141 : 238-247.
19. Marty N., et al. 1998. The role of the Pseudomonas aeruginosa exopolysaccharide in adherence to human tracheal cells. J Med Microbiol 47 : 129-134.
20. Doring G., Albus A., Høiby N. 1988. Immunologic aspects of cystic fibrosis. Chest 94 : S1095-S1145.
21. Michel-Briand Y., Grandguillot M. 1991. Facteurs de pathogénicité de Pseudomonas aeruginosa et critères permettant de valider son pouvoir pathogène. Lettre Infect 1 : 3-6.
22. Pier C.B, Grout M., Zaidi T.S. 1996. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271 : 64-67.
23. Wilson C.B. 1996. The immune system : the devie within on the Good Guy. Pediatr Pulmonol S13 : 75.
24. Moss R. 1996. Pathways on inflammation in cystic fibrosis. Pediatr Pulmonol S1 : 158-159.
25. Wiener-Kronish J.P., Frank D.W., Heiszig M.J., Sawa T. 1996 The different host responses to Pseudomonas aeruginosa : the implication of therapy. Pediatr Pulmonol S13 : 144-145.
26. Høiby N., Koch C. 1990. Pseudomonas aeruginosa infection in CF and its management. Thorax 45 : 881-884.
27. Stutman H.R. 1996. Approch to CF related pulmonary infection in the US. In : Cystic fibrosis pulmonary infections. Bâle : Berkhauser Verlag 27-29.
28. Ramsey B.W., Pope M., Warren J.W. 1994. Pulmonary exacerbation : how do we define it ? In : 8ht annual North American CF conference proceedings. New-York : Wiley-Liss, 180 p.
29. Navarro J. 1993. Vision actuel le et perspectives de la thérapeutique dans la mucoviscidose. Bull Acad Nat Med 177 : 413-424.
30. Bingen E., et al. 1992. Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 31 : 2589-2593.
31. Codart C., Plesiat R., Michel-Briand Y. 1993. Persistance of Pseudomonas aeruginosa strains in seven cystic fibrosis patients followed over 20 months. Eur J Med 2 : 117-120.
32. Dournes J.L., Marty N., Chabanon G. 1994. Pseudomonas aeruginosa, ses marqueurs épidémiologiques. Lettre Infect 9 : 432-439.
33. Isles A., et al. 1984. Pseudomonas cepacia infection in cystic fibrosis : an emerging problem. J Pediatr 104 : 206-210.
34. Saiman O., Martone W., Jarvis W. 1987. The epidemiology of Pseudomonas cepacia in patients with cystic fibrosis. EurJ Epidemiol 3 : 336-342.
35. Govan J.R., et al. 1993. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 342 : 15-19.
36. Lewin L.O., Byard P.J., Davis P.B. 1990. Effect of Pseudomonas colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol 43 : 125-131.
37. Segonds C., Chabanon C., Couetdic G., Michel-Briand Y., Bingen E., and the French Observatoire Burkholderia cepacia Study Group. 1996. Epidemiology of pulmonary colonization with Burkholderia cepacia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 15 : 841-482.
38. Anonyme. 1992. Pseudomonas cepacia more than a harmless commensal. Lancet 339 : 1385-1386.
39. Sajjan U., Corey M., Karmali M., Forstner J. 1992. Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cytic fibrosis. J Clin Invest 89 : 648-656.
40. Goldstein R. 1995. Structurally variant classes of pilus appendage fibers co expression from Burkholderia cepacia. J Bact 177 : 1039-1052.
41. Sun L., et al. 1995. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemia in North America and Britain. Nature Med 1 : 661-666.
42. Saiman L., Cacalano G., Prince A. 1990 Pseudomonas cepacia adherence to respiratory epithelial cells is enhanced by Pseudomonas aeruginosa. Infect Immun 58 : 2578-2584.
43. Meyer J.M., Hohnadel D., Halle F. 1989. Cepabactin from Pseudomonas cepacia, a new type of siderophore. J Gen Microbiol 135 : 1479-1487.
44. McKevitt A.I., Bajaksouzian S., Klinger J.D, Woods D.E. 1989. Purification and characterization of a extracellular protease from Pseudomonas cepacia. Infec Immun 57 : 771-778.
45. Gessner A.R., Mortensen J.E. 1990. Pathogenic factors of Pseudomonas cepacia isolates from patients with cystic fibrosis. J Med Microbiol 33 : 115-120.
46. Marty N., Dournes J.L, Chabanon G., Montrozier H. 1992. Influence of nutrient media on the chemical composition of the exopolysaccharide from mucoid and non mucoid Pseudomonas aeruginosa. FEMS Microbiol Lett 98 : 35-44.
47. Cerentola S., Marty N., Montrozier H. 1996. Structural studies of the acidic exopolysaccharide produced by a mucoid strain of Burkholderia cepacia isolated from cystic fibrosis. Carbohydrate Research 285 . 59-67.
48. Pasquier C., Marty N., Dournes J.L., Chabanon G., Pipy B. 1997. Implication of neutral polysaccharides associated to alginate in inhibition of murine macrophages response to Pseudomonas aeruginosa. FEMS Microbiol Lett 147 : 195-204.
49. Speert D., Bond Y., Woodman R.C., Curnutte J.T. 1994. Infection with Pseudomonas cepacia in chronic granulomatous disease : role of non-oxidative killing by neutrophils in host defense. J Clin Invest 170 : 1524-1531.
50. Nelson J.W., Butler S.L., Krieg D., Govan J.R.W. 1994. Virulence factors of Burkholderia cepacia. FEMS Immunol Med Microbiol 8 : 89-98.
51. Segonds C , Marty N., Agueda L., Chabanon G. 1995. Pseudomonas cepacia : la percée d'un opportuniste. Rev Fr Labo 274 . 87-93.
52. Segonds C, Chabanon G. 1997. Polymerase chain reaction (PCR) restriction fragmentanalysis of 16rDNA as an identifical tool for Burkholderia cepacia and closely related species recovered from patients with cystic fibrosis. 21st European cystic fibrosis conference, Davos 1-6 juin 1997.
53. Bingen E., et al. 1993. Arbitrarily primed polymerase chain reaction is a rapid method to differentiate crossed from independant Pseudomonas cepacia infections in cystic fibrosis patients. J Clin Microbiol 31 : 2589-2593.
54. Segonds C., et al. 1997. Genotypic analysis of Burkholderia cepacia isolates in 13 French cystic fibrosis centres. J Clin Microbiol 35 : 2055-2060.
55. Chatelut M., Dournes J.L, Chabanon G., Marty N. 1995. Epidemiological typing of Xanthomonas maltophilia by PCR. J Clin Microbiol 33 : 912-914
56. Kinney J.S., Little B.J., Jilken R.H., Rosenstein B.J. 1989. Mycobacterium avium complex in a patient with cystic fibrosis : disease vs colonization. Pediatr Infect Dis 8 : 393-396.
57. Abman S.H., Ogle J.W., Bulter-Simon N., Rumack C.M., Accurso FJ. 1988. Role of respiratory syncitial virus in early hospitalization for respiratory distress of young infants with cystic fibrosis. J Pediatr 133 : 826-830.